PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Heparin more effective than bivalirudin in patients during emergency heart procedure

Study comparing 2 anti-clotting medications finds fewer repeat heart attacks with heparin

2014-03-31
(Press-News.org) WASHINGTON (March 31, 2014) — In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

The single-center, open label trial enrolled 1,829 patients with suspected heart attack who received a coronary angiography, an imaging test to see how blood flows through the heart. Patients were randomized to receive unfractionated heparin or bivalirudin – medications that block the body's natural clot formation process and are routinely given during this procedure. Patients were followed for 28 days to examine the primary endpoint – a composite of all-cause death, stroke, repeat heart attack or unplanned repeat procedure. Data showed that patients taking bivalirudin had a significantly higher incidence of these outcomes at 8.7 percent compared with 5.7 percent of those in the heparin group. The largest difference between the groups was in the incidence of repeat heart attack caused by stent thrombosis, blocking of the stent with a new blood clot (3.4 percent in the bivalirudin group compared to 0.9 percent receiving heparin). There was no statistically significant difference in the primary safety outcome of major bleeding between groups (3.5 percent bivalirudin compared to 3.1 percent heparin).

"Both heparin and bivalirudin are used regularly worldwide in percutaneous coronary intervention, but there is still some debate about whether one drug has any advantage over the other," said Adeel Shahzad, M.B.B.S., M.R.C.P., cardiologist at the Liverpool Heart and Chest Hospital and one of the lead investigators of the study. "We sought to evaluate the drugs by comparing outcomes in two well-matched groups of patients, and our study suggests that heparin may be a more effective agent."

All patients who reported to the study site with a possible heart attack between February 2012 and November 2013 were assessed for inclusion in the study. Eligible patients were immediately randomized to one of the two study groups for emergency treatment. Percutaneous coronary intervention was performed in 82 percent of patients, with similar procedural success in both groups (97.5 percent in bivalirudin compared to 97.3 percent in heparin group). Because of the life-threatening nature of the situation at time of enrollment – and routine use of both trial medications – researchers obtained approval to get patients' delayed consent. Of 1,829 treated patients, only four later refused or withdrew consent.

Patients received dual antiplatelet therapy – a combination of aspirin and another antiplatelet agent that together inhibit blood clotting – before their procedures as part of the routine practice at the study site. Those in the heparin group received a bolus dose of unfractionated heparin of 70 units/kg (1 kg = 2.2 lbs) pre-procedure, while bivalirudin was given as a bolus of 0.75mg/kg, followed by an infusion of 1.75 mg/kg per hour for the duration of the procedure.

Percutaneous coronary intervention – also called angioplasty – is a procedure to open the blood vessels that supply blood to the heart after they have become narrowed or blocked. A catheter is inserted through the leg or wrist and threaded through the blood vessel to the heart. A small, metal mesh tube called a stent is often placed during this procedure to help the artery stay open. Patients receive medication during the procedure to help block the body's natural blood clot formation process.

According to Shahzad, the routine use of heparin has the potential to reduce costs for health care providers, as the cost of bivalirudin can be much higher than heparin.

Although previous studies have compared bivalirudin to heparin, these studies have tested bivalirudin against a combination of heparin and another anti-clotting agent called a glycoprotein IIb/IIIa inhibitor. These studies have often shown a higher rate of bleeding in the heparin group, but Shahzad said it is difficult to know whether this was because patients were receiving two anti-clotting agents together.

Glycoprotein IIb/IIIa inhibitors were used for this study in special circumstances under current guidelines – for example, in patients with massive blood clots. Use of this medication was comparable in both groups (13.5 percent of bivalirudin patients compared to 15.5 percent of heparin), and there were no significant differences between the two treatment groups in terms of bleeding complications.

Interpretation of the study data may be limited due to single-center recruitment, the open label study design and predominantly Caucasian population. However, according to authors, this is both the largest ever single-center trial in cardiovascular medicine, as well as the first major trial to recruit 100 percent of all eligible patients, and study findings represent a true, unselected population of angioplasty patients.

Shahzad said that further research should be done to determine the best use of glycoprotein inhibitors.

INFORMATION: Support for the study was provided by unrestricted grants from The Medicines Company, Parsippany, N.J., and AstraZeneca, Wilmington, Del.

The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC14 for the latest news from the meeting.

The American College of Cardiology is a nonprofit medical society comprised of 47,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit CardioSource.org.


ELSE PRESS RELEASES FROM THIS DATE:

Anti-anxiety drugs and sleeping pills linked to risk of death

2014-03-31
Anti-anxiety drugs and sleeping pills have been linked to an increased risk of death, according to new research from the University of Warwick. The large study, published in BMJ, shows that several anxiolytic (anti-anxiety) drugs or hypnotic drugs (sleeping pills) are associated with a doubling in the risk of mortality. Although these findings are based on routine data and need to be interpreted cautiously, the researchers recommended that a greater understanding of their impact is essential. Professor Scott Weich, Professor of Psychiatry at the University of ...

Drug-eluting stents demonstrate better outcomes after 1 year than bare metal stents

2014-03-31
WASHINGTON (March 31, 2014) — Use of drug-eluting stents is associated with a lower risk of major cardiovascular events at one year compared to bare metal stents when followed by an individualized course of blood-thinning medication among patients previously thought to be uncertain candidates for drug-eluting stents due to their heightened risk of bleeding or blood clots, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. Positive study findings for patients receiving a shorter than currently recommended course of ...

Never say never in the nano-world

Never say never in the nano-world
2014-03-31
This news release is available in German. Objects with sizes in the nanometer range, such as the molecular building blocks of living cells or nanotechnological devices, are continuously exposed to random collisions with surrounding molecules. In such fluctuating environments the fundamental laws of thermodynamics that govern our macroscopic world need to be rewritten. An international team of researchers from Barcelona, Zurich and Vienna found that a nanoparticle trapped with laser light temporarily violates the famous second law of thermodynamics, something that ...

New human trial shows stem cells are effective for failing hearts

2014-03-31
WASHINGTON (March 31, 2014) — Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. "Our results show that this stem cell treatment is safe and it improves heart function when compared to placebo," said Anders Bruun Mathiasen, M.D., research fellow in the Cardiac Catherization Lab at Rigshospitalet University Hospital Copenhagen, and lead investigator ...

Real-world heart procedure results consistent with scientific research

2014-03-31
WASHINGTON (March 31, 2014) — The first one-year outcomes data of transcatheter heart valve replacement (TAVR) in nearly all U.S. patients undergoing this procedure shows that real-world outcomes are comparable to or slightly better than those found in clinical trials, according to registry data presented at the American College of Cardiology's 63rd Annual Scientific Session. However, specific baseline characteristics of patients undergoing TAVR are associated with differing degrees of death and survival and may be important considerations for patient counseling and shared ...

Newly discovered molecule may offer hope for immune disorders and runaway inflammation

2014-03-31
A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells). With this understanding, it may be possible to develop new therapies that essentially shut down dendritic cell activity, and thereby reducing an immune reaction. "We hope that our findings provide better understanding of immune regulation, which ...

NASA releases images of X-class solar flare

NASA releases images of X-class solar flare
2014-03-31
The sun emitted a significant solar flare, peaking at 1:48 p.m. EDT March 29, 2014, and NASA's Solar Dynamics Observatory captured images of the event. Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth's atmosphere to physically affect humans on the ground, however -- when intense enough -- they can disturb the atmosphere in the layer where GPS and communications signals travel. To see how this event impacted Earth, please visit NOAA's Space Weather Prediction Center at http://spaceweather.gov, the U.S. government's ...

Stats show growth of breast lifts outpacing implants 2 to 1

Stats show growth of breast lifts outpacing implants 2 to 1
2014-03-31
VIDEO: New statistics from the American Society of Plastic Surgeons show that since 2000, breast lift procedures have grown by 70 percent, twice the rate of breast implants. According to the... Click here for more information. ARLINGTON HEIGHTS, Ill., March 31, 2014 – New statistics released today by the American Society of Plastic Surgeons (ASPS) show that breast lift procedures are growing at twice the rate of breast implant surgeries. Since 2000, breast lifts have grown by ...

Comparison of drug-releasing stents show similar safety outcomes after 2 years

2014-03-31
A comparison of the safety of biodegradable polymer biolimus-eluting stents vs durable polymer everolimus-eluting stents finds similar outcomes for measures including death and heart attack after two years, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. Recent studies have raised concerns about the safety of biodegradable polymer drug-eluting stents (BP-DES) compared with durable polymer everolimus-eluting stents (DP-EES). The NOBORI Biolimus-Eluting vs XIENCE/PROMUS Everolimus-Eluting ...

Six new Dracula ants from Madagascar: Minor workers become queens in Mystrium

Six new Dracula ants from Madagascar: Minor workers become queens in Mystrium
2014-03-31
Six new species of Dracula ants from the Malagasy region have been discovered by scientists at the California Academy of Sciences. The discoveries, by postdoctoral fellow Masashi Yoshimura from Japan and curator of entomology Brian L. Fisher, represent a completely new twist in the typically rigid caste system of ants, where anatomy is typically destiny. The study was published in the open access journal ZooKeys. "The genus Mystrium is the most mysterious group within the bizarre Dracula ants," said Yoshimura. Mystrium species have unique features such as long, spatulate ...

LAST 30 PRESS RELEASES:

Andrew Siemion to receive the SETI Institute’s 2024 Drake Award

New study shows how the Crimean-Congo hemorrhagic fever virus enters our cells

Neoadjuvant chemotherapy proves effective for locally advanced penile squamous cell carcinoma

Study flips treatment paradigm in bilateral Wilms tumor, shows resistance to chemotherapy may point toward favorable outcomes

Doctors received approximately $12.1 billion from drug and device makers between 2013-2022

Discovery suggests new strategy against follicular lymphoma

Making the future too bright: how wishful thinking can point us in the wrong direction

Ochsner Health named to Newsweek’s America’s Greatest Workplaces 2024 for Job Starters

Three-year study of young stars with NASA’s Hubble enters new chapter

North Carolina takes the lead in PFAs research with Collaboratory’s $3 million investment to expand the state’s research capacity

Is it the school, or the students?

Exploring the relationship between HIV pre-exposure prophylaxis and the incidence of chlamydia, gonorrhea and syphilis – findings from Denmark

Music: Song lyrics have become simpler and more repetitive since 1980

Environment: More than half of Colorado River’s water used to irrigate crops

When inequality is more than “skin-deep”: Social status leaves traces in the epigenome of spotted hyenas in Tanzania

Study explores the future of at-home cancer treatment

First performance standards published to measure the effectiveness of lifestyle medicine treatments

To keep volunteers, connect them

Suppressing boredom at work hurts future productivity, study shows

Older brain cells linger unexpectedly before their death

Clear shift in arterial diseases in diabetes

Celebrating half a century of pioneering excellence: EBMT marks its 50th anniversary

Ancient DNA reveals the appearance of a 6th century Chinese emperor

DNA study IDs descendants of George Washington from unmarked remains, findings to aid service member IDs going back to World War II

Familial Alzheimer’s disease transferred via bone marrow transplant in mice

Perspectives of oncologists on the ethical implications of using AI for cancer care

Industry payments to US physicians by specialty and product type

Andrew E. Place, MD, PhD appointed as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Vice President, Pediatric Chief Medical Officer

COVID-19 antibody discovery could explain long COVID

Wild plants face viral surprise

[Press-News.org] Heparin more effective than bivalirudin in patients during emergency heart procedure
Study comparing 2 anti-clotting medications finds fewer repeat heart attacks with heparin